Trinity Annual Drug Index

Evaluating the Commercial Performances of Novel Drugs Approved in 2020

Home / Intelligence / White Papers / Trinity Annual Drug Index

This report, the sixth in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the commercial performance over three years of novel drugs approved by the FDA in 2020, with commercial, therapeutic value and R&D investment scores for each. 2020 saw 58 unique drug and biologic approvals, of which the majority were Oncology (29%) followed by Neurology (16%). In this report we describe the notable themes and trends within the industry and take a deeper look into a few products with outstanding performance. The COVID-19 pandemic, which swept the globe in 2020, brought unprecedented challenges and disruptions to the pharmaceutical industry, reshaping priorities and accelerating research efforts towards finding innovative solutions.

Interested in hearing expert discussion on this white paper?

View our on-demand webinar.

Complete the form below to access the full white paper

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email

Related Intelligence